At Anziva Pharmaceuticals, we are building a portfolio of non opioid, non invasive pain management therapies. Each program is designed to enhance patient outcomes while avoiding the risks of addictive drugs or invasive procedures. By using the FDA 505(b)(2) pathway, we accelerate development timelines, lower costs, and bring innovative solutions to patients sooner.